<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; AWACS</title>
	<atom:link href="http://www.tapanray.in/tag/awacs/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>The Recent Ban On Irrational FDCs: History Repeats Itself</title>
		<link>http://www.tapanray.in/the-recent-ban-on-irrational-fdcs-history-repeats-itself/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-recent-ban-on-irrational-fdcs-history-repeats-itself</link>
		<comments>http://www.tapanray.in/the-recent-ban-on-irrational-fdcs-history-repeats-itself/#comments</comments>
		<pubDate>Mon, 21 Mar 2016 00:00:49 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[294]]></category>
		<category><![CDATA[344]]></category>
		<category><![CDATA[59th]]></category>
		<category><![CDATA[ADE]]></category>
		<category><![CDATA[ADR]]></category>
		<category><![CDATA[AIOCD]]></category>
		<category><![CDATA[AWACS]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Combination]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[Corex]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Delhi]]></category>
		<category><![CDATA[Dose]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[DTAB]]></category>
		<category><![CDATA[evidence]]></category>
		<category><![CDATA[FDCs]]></category>
		<category><![CDATA[Fixed]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[history]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[injunction]]></category>
		<category><![CDATA[interim]]></category>
		<category><![CDATA[irrational]]></category>
		<category><![CDATA[itself]]></category>
		<category><![CDATA[Kokate]]></category>
		<category><![CDATA[madras]]></category>
		<category><![CDATA[Ministry]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[repeats]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Sri Lanka]]></category>
		<category><![CDATA[stay]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7543</guid>
		<description><![CDATA[The recent regulatory ban on a large number of irrational Fixed Dose Combination (FDC) drugs is not a new incident in India. A similar mega ban was announced even before, about nine years ago. Intriguingly, the saga continues, for various &#8230; <a href="http://www.tapanray.in/the-recent-ban-on-irrational-fdcs-history-repeats-itself/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-recent-ban-on-irrational-fdcs-history-repeats-itself/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is Drug Price Control The Key Growth Barrier For Indian Pharma Industry?</title>
		<link>http://www.tapanray.in/is-drug-price-control-the-key-growth-barrier-for-indian-pharma-industry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-drug-price-control-the-key-growth-barrier-for-indian-pharma-industry</link>
		<comments>http://www.tapanray.in/is-drug-price-control-the-key-growth-barrier-for-indian-pharma-industry/#comments</comments>
		<pubDate>Mon, 19 Oct 2015 00:00:14 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[1995]]></category>
		<category><![CDATA[2011]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[AIOCD]]></category>
		<category><![CDATA[AIOCD-AWACS]]></category>
		<category><![CDATA[apex]]></category>
		<category><![CDATA[Atorvastatin]]></category>
		<category><![CDATA[AWACS]]></category>
		<category><![CDATA[barrier]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[consumer]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[corollary]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Crocin Advance]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[driver]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Essential]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[health care UHC]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[hikes]]></category>
		<category><![CDATA[IMS]]></category>
		<category><![CDATA[increases]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[IPM]]></category>
		<category><![CDATA[key]]></category>
		<category><![CDATA[Maharashtra]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[Para 19]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[safeguard]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Universal]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7183</guid>
		<description><![CDATA[The corollary of the above headline could well be: “Are drug price hikes the key growth driver for the Indian Pharmaceutical Market (IPM)?” Whenever the first question, as appears in the headline of this article: “Is drug price control a &#8230; <a href="http://www.tapanray.in/is-drug-price-control-the-key-growth-barrier-for-indian-pharma-industry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-drug-price-control-the-key-growth-barrier-for-indian-pharma-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Price Control in India: A Fresh Advocacy With Blunt Edges</title>
		<link>http://www.tapanray.in/drug-price-control-in-india-a-fresh-advocacy-with-blunt-edges/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-price-control-in-india-a-fresh-advocacy-with-blunt-edges</link>
		<comments>http://www.tapanray.in/drug-price-control-in-india-a-fresh-advocacy-with-blunt-edges/#comments</comments>
		<pubDate>Mon, 07 Sep 2015 00:00:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2011]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[advocacy]]></category>
		<category><![CDATA[AIOCD]]></category>
		<category><![CDATA[Authority]]></category>
		<category><![CDATA[AWACS]]></category>
		<category><![CDATA[blunt]]></category>
		<category><![CDATA[campaign]]></category>
		<category><![CDATA[capita]]></category>
		<category><![CDATA[cheapest]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[cutting]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[edges]]></category>
		<category><![CDATA[Failure]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[IMS]]></category>
		<category><![CDATA[income]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Make in India]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[Para 19]]></category>
		<category><![CDATA[parity]]></category>
		<category><![CDATA[per]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Pharmasofttech]]></category>
		<category><![CDATA[power]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[purchasing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Subburaj]]></category>
		<category><![CDATA[Sun Pharma]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Yeh dil maange more]]></category>
		<category><![CDATA[“Assessing the Impact of Price Control Measures on Access to Medicines in India”]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7017</guid>
		<description><![CDATA[It is no-brainer that the advocacy initiatives to influence the new Government doing away with the ‘Drug Price Control’ in India has re-started by flooring the gas pedal. A fresh invigorating effort, apparently a pretty expensive one, has been initiated &#8230; <a href="http://www.tapanray.in/drug-price-control-in-india-a-fresh-advocacy-with-blunt-edges/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-price-control-in-india-a-fresh-advocacy-with-blunt-edges/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>“Make in India” Image of Pharma Needs An Early Makeover</title>
		<link>http://www.tapanray.in/make-in-india-image-of-pharma-needs-an-early-makeover/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=make-in-india-image-of-pharma-needs-an-early-makeover</link>
		<comments>http://www.tapanray.in/make-in-india-image-of-pharma-needs-an-early-makeover/#comments</comments>
		<pubDate>Mon, 20 Apr 2015 00:00:28 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AIOCD]]></category>
		<category><![CDATA[AllianceBoots]]></category>
		<category><![CDATA[Amerisource –Bergen]]></category>
		<category><![CDATA[AWACS]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Celesio]]></category>
		<category><![CDATA[CVS Caremark]]></category>
		<category><![CDATA[Data Integrity.]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[GMP]]></category>
		<category><![CDATA[image]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Ipca]]></category>
		<category><![CDATA[Make in India]]></category>
		<category><![CDATA[makeover]]></category>
		<category><![CDATA[McKesson]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Ministry of Commerce]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[pharma export]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[pharmacy distributors]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Stefano Pessina]]></category>
		<category><![CDATA[Sun Pharma]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[Walgreen]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6549</guid>
		<description><![CDATA[“It is never too late to be what you might have been” - George Elliot The chronicle of events since the last couple of years or so, related to ‘Make in India’ image of the local drug industry, have been instrumental &#8230; <a href="http://www.tapanray.in/make-in-india-image-of-pharma-needs-an-early-makeover/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/make-in-india-image-of-pharma-needs-an-early-makeover/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Takeover Magician To Tango Again On A Bold New ‘Sunny’ Tune</title>
		<link>http://www.tapanray.in/the-takeover-magician-to-tango-again-on-a-bold-new-sunny-tune/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-takeover-magician-to-tango-again-on-a-bold-new-sunny-tune</link>
		<comments>http://www.tapanray.in/the-takeover-magician-to-tango-again-on-a-bold-new-sunny-tune/#comments</comments>
		<pubDate>Mon, 14 Apr 2014 00:00:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AIOCD]]></category>
		<category><![CDATA[ANDA]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[AWACS]]></category>
		<category><![CDATA[cadila]]></category>
		<category><![CDATA[CBI]]></category>
		<category><![CDATA[cGMP]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Daiichi]]></category>
		<category><![CDATA[Dilip]]></category>
		<category><![CDATA[Diovan]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IPM]]></category>
		<category><![CDATA[magic]]></category>
		<category><![CDATA[magician]]></category>
		<category><![CDATA[nexium]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sankyo]]></category>
		<category><![CDATA[Shanghvi]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[sunny]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[takeover]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[US-FDA]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[wand]]></category>
		<category><![CDATA[wockhardt]]></category>
		<category><![CDATA[Zydus]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5240</guid>
		<description><![CDATA[The consolidation process of the Indian pharmaceutical industry continues in its own pace. Most recently, the homegrown pharma takeover magician is all set to tango yet again with a bold ‘Sunny’ tune. The low profile creator of high value ‘Sun &#8230; <a href="http://www.tapanray.in/the-takeover-magician-to-tango-again-on-a-bold-new-sunny-tune/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-takeover-magician-to-tango-again-on-a-bold-new-sunny-tune/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Indian Pharmaceutical Market in February 2014 &#8211; A Snap Shot</title>
		<link>http://www.tapanray.in/indian-pharmaceutical-market-in-february-2014-a-snap-shot/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indian-pharmaceutical-market-in-february-2014-a-snap-shot</link>
		<comments>http://www.tapanray.in/indian-pharmaceutical-market-in-february-2014-a-snap-shot/#comments</comments>
		<pubDate>Wed, 12 Mar 2014 00:00:58 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2014]]></category>
		<category><![CDATA[AIOCD]]></category>
		<category><![CDATA[AWACS]]></category>
		<category><![CDATA[February]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[IPM]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[snapshot]]></category>
		<category><![CDATA[Tapan]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5086</guid>
		<description><![CDATA[According to the Retail Audit dated March 2014 of well reputed AIOCD Pharmasofttech AWACS Pvt. Ltd, in the month of February 2014, the Indian Pharmaceutical Market (IPM) registered a turnover of 5902 Crore (around US$ 980 million) growing at 4.5 percent against &#8230; <a href="http://www.tapanray.in/indian-pharmaceutical-market-in-february-2014-a-snap-shot/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indian-pharmaceutical-market-in-february-2014-a-snap-shot/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A Snap Shot of Indian Pharmaceutical Market in January 2014</title>
		<link>http://www.tapanray.in/a-snap-shot-of-indian-pharmaceutical-market-in-january-2014/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-snap-shot-of-indian-pharmaceutical-market-in-january-2014</link>
		<comments>http://www.tapanray.in/a-snap-shot-of-indian-pharmaceutical-market-in-january-2014/#comments</comments>
		<pubDate>Fri, 14 Feb 2014 12:05:18 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AWACS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[IPM]]></category>
		<category><![CDATA[January 2014]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[MNCs]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[snapshot]]></category>
		<category><![CDATA[Tapan]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4997</guid>
		<description><![CDATA[According to the retail audit dated February 2014 of well reputed AIOCD Pharmasofttech AWACS Pvt. Ltd, in January 2014 the Indian Pharmaceutical Market (IPM) registered a turnover of Rs. 6,227 Crore (around US$1 billion) with a growth of 8.5 percent. &#8230; <a href="http://www.tapanray.in/a-snap-shot-of-indian-pharmaceutical-market-in-january-2014/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-snap-shot-of-indian-pharmaceutical-market-in-january-2014/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New Drug Price Control Order of India: Is it Directionally Right Improving Access to Medicines?</title>
		<link>http://www.tapanray.in/new-drug-price-control-order-of-india-is-it-directionally-right-improving-access-to-medicines/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=new-drug-price-control-order-of-india-is-it-directionally-right-improving-access-to-medicines</link>
		<comments>http://www.tapanray.in/new-drug-price-control-order-of-india-is-it-directionally-right-improving-access-to-medicines/#comments</comments>
		<pubDate>Mon, 27 May 2013 00:00:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2002]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[accuracy]]></category>
		<category><![CDATA[AIOCD]]></category>
		<category><![CDATA[AWACS]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[benefit]]></category>
		<category><![CDATA[ceiling]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[Challenging]]></category>
		<category><![CDATA[CO]]></category>
		<category><![CDATA[consumers]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[DPCO2013]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Essential]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[implementation]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Karnataka]]></category>
		<category><![CDATA[litigation]]></category>
		<category><![CDATA[margin]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[methodology]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[NLEM 2011]]></category>
		<category><![CDATA[notification]]></category>
		<category><![CDATA[Order]]></category>
		<category><![CDATA[outsourced]]></category>
		<category><![CDATA[overview]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[retail]]></category>
		<category><![CDATA[Ringside]]></category>
		<category><![CDATA[span]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[view]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2546</guid>
		<description><![CDATA[The last Drug Policy of India was announced in 2002, which was subsequently challenged by a Public Interest Litigation (PIL) in the Karnataka High Court on the ground of being inflationary in nature. The Honorable Court by its order dated &#8230; <a href="http://www.tapanray.in/new-drug-price-control-order-of-india-is-it-directionally-right-improving-access-to-medicines/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/new-drug-price-control-order-of-india-is-it-directionally-right-improving-access-to-medicines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
